213 related articles for article (PubMed ID: 34924820)
1. Implication of ARID1A Undercurrents and PDL1, TP53 Overexpression in Advanced Gastric Cancer.
Qadir J; Majid S; Khan MS; Rashid F; Wani MD; Bhat SA
Pathol Oncol Res; 2021; 27():1609826. PubMed ID: 34924820
[TBL] [Abstract][Full Text] [Related]
2. Prognostic role of ARID1A negative expression in gastric cancer.
Ashizawa M; Saito M; Min AKT; Ujiie D; Saito K; Sato T; Kikuchi T; Okayama H; Fujita S; Endo H; Sakamoto W; Momma T; Ohki S; Goto A; Kono K
Sci Rep; 2019 May; 9(1):6769. PubMed ID: 31043675
[TBL] [Abstract][Full Text] [Related]
3. Loss of ARID1A expression is associated with systemic inflammation markers and has important prognostic significance in gastric cancer.
Wang X; Che K; Shi T; Liu Q; Xu X; Wu H; Yu L; Liu B; Wei J
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1583-1595. PubMed ID: 35294647
[TBL] [Abstract][Full Text] [Related]
4. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer.
Wang DD; Chen YB; Pan K; Wang W; Chen SP; Chen JG; Zhao JJ; Lv L; Pan QZ; Li YQ; Wang QJ; Huang LX; Ke ML; He J; Xia JC
PLoS One; 2012; 7(7):e40364. PubMed ID: 22808142
[TBL] [Abstract][Full Text] [Related]
5. ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation.
Kase K; Saito M; Nakajima S; Takayanagi D; Saito K; Yamada L; Ashizawa M; Nakano H; Hanayama H; Onozawa H; Okayama H; Endo H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Shiraishi K; Kohno T; Kono K
Carcinogenesis; 2021 Feb; 42(1):21-30. PubMed ID: 33196828
[TBL] [Abstract][Full Text] [Related]
6. Uncovering the dosage-dependent roles of Arid1a in gastric tumorigenesis for combinatorial drug therapy.
Loe AKH; Francis R; Seo J; Du L; Wang Y; Kim JE; Hakim SW; Kim JE; He HH; Guo H; Kim TH
J Exp Med; 2021 Jun; 218(6):. PubMed ID: 33822841
[TBL] [Abstract][Full Text] [Related]
7. Unique characteristics of
Kim YS; Jeong H; Choi JW; Oh HE; Lee JH
Saudi J Gastroenterol; 2017; 23(5):268-274. PubMed ID: 28937020
[TBL] [Abstract][Full Text] [Related]
8. MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in gastric cancer cells.
Tong G; Cheng B; Li J; Wu X; Nong Q; He L; Li X; Li L; Wang S
Cancer Med; 2019 Nov; 8(16):7044-7054. PubMed ID: 31557409
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of ARID1A mutations with mRNA levels and protein expression in gastric carcinoma.
Hwang I; Cho Y; Kang SY; Kim DG; Ahn S; Lee J; Kim KM
Pathol Res Pract; 2024 Mar; 255():155063. PubMed ID: 38324965
[TBL] [Abstract][Full Text] [Related]
10. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer.
Mehrvarz Sarshekeh A; Alshenaifi J; Roszik J; Manyam GC; Advani SM; Katkhuda R; Verma A; Lam M; Willis J; Shen JP; Morris J; Davis JS; Loree JM; Lee HM; Ajani JA; Maru DM; Overman MJ; Kopetz S
Clin Cancer Res; 2021 Mar; 27(6):1663-1670. PubMed ID: 33414133
[TBL] [Abstract][Full Text] [Related]
11. Loss of ARID1A Expression is Related to Gastric Cancer Progression, Epstein-Barr Virus Infection, and Mismatch Repair Deficiency.
Han N; Kim MA; Lee HS; Kim WH
Appl Immunohistochem Mol Morphol; 2016; 24(5):320-5. PubMed ID: 26067140
[TBL] [Abstract][Full Text] [Related]
12. Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis.
Reske JJ; Wilson MR; Holladay J; Siwicki RA; Skalski H; Harkins S; Adams M; Risinger JI; Hostetter G; Lin K; Chandler RL
PLoS Genet; 2021 Dec; 17(12):e1009986. PubMed ID: 34941867
[TBL] [Abstract][Full Text] [Related]
13. AT-rich Interaction Domain 1A Gene Variations: Genetic Associations and Susceptibility to Gastric Cancer Risk.
Qadir J; Majid S; Khan MS; Rashid F; Wani MD; Din I; Bashir H
Pathol Oncol Res; 2020 Oct; 26(4):2237-2246. PubMed ID: 32377988
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral heterogeneity and loss of ARID1A expression in gastric cancer correlates with increased PD-L1 expression in Western patients.
Tober JM; Halske C; Behrens HM; Krüger S; Röcken C
Hum Pathol; 2019 Dec; 94():98-109. PubMed ID: 31704366
[TBL] [Abstract][Full Text] [Related]
15. Promoter hypermethylation of ARID1A gene is responsible for its low mRNA expression in many invasive breast cancers.
Zhang X; Sun Q; Shan M; Niu M; Liu T; Xia B; Liang X; Wei W; Sun S; Zhang Y; Liu XS; Song Q; Yang Y; Ma Y; Liu Y; Yang L; Ren Y; Zhang G; Pang D
PLoS One; 2013; 8(1):e53931. PubMed ID: 23349767
[TBL] [Abstract][Full Text] [Related]
16. Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1.
Zhang Q; Yan HB; Wang J; Cui SJ; Wang XQ; Jiang YH; Feng L; Yang PY; Liu F
Oncotarget; 2016 Jul; 7(29):46127-46141. PubMed ID: 27323812
[TBL] [Abstract][Full Text] [Related]
17. MiR-34a suppresses the proliferation and invasion of gastric cancer by modulating PDL1 in the immune microenvironment.
Yong H; Fu J; Gao G; Shi H; Zheng D; Zhou X
Mol Cell Probes; 2020 Oct; 53():101601. PubMed ID: 32445780
[TBL] [Abstract][Full Text] [Related]
18. A CRISPR/Cas9-Engineered
Lo YH; Kolahi KS; Du Y; Chang CY; Krokhotin A; Nair A; Sobba WD; Karlsson K; Jones SJ; Longacre TA; Mah AT; Tercan B; Sockell A; Xu H; Seoane JA; Chen J; Shmulevich I; Weissman JS; Curtis C; Califano A; Fu H; Crabtree GR; Kuo CJ
Cancer Discov; 2021 Jun; 11(6):1562-1581. PubMed ID: 33451982
[TBL] [Abstract][Full Text] [Related]
19. Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy.
Gu Y; Zhang P; Wang J; Lin C; Liu H; Li H; He H; Li R; Zhang H; Zhang W
Cancer Immunol Immunother; 2023 May; 72(5):1199-1208. PubMed ID: 36369379
[TBL] [Abstract][Full Text] [Related]
20. PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab.
Wang H; Shan Q; Guo J; Han X; Zhao C; Li H; Wang Z
Lung Cancer; 2021 Jan; 151():76-83. PubMed ID: 33246647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]